Enigma Diagnostics Announces New San Diego Office and Appointment of Joel Centeno, VP Regulatory & Quality

OXFORD, England and SAN DIEGO, March 4, 2010 - Enigma Diagnostics Limited, the decentralised and point-of-care molecular
diagnostics company, announced today the opening of its new Regional HQ
office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory
& Quality.

The new 17,000sq ft premises on Nancy Ridge Drive in Sorrento Valley will
provide Enigma with access to the deep resource pool of San Diego based in
vitro diagnostics (IVD) professionals. Enigma anticipates US office growth
throughout 2010 to provide experience in sales & marketing, assay
development, regulatory and manufacturing activities.

Joel Centeno joins Enigma as VP Regulatory & Quality, US and will be
responsible for obtaining appropriate regulatory approval for Enigma's rapid
diagnostic instrument systems and products. Joel brings extensive executive
experience in quality system design & implementation, new product development
in molecular diagnostics and clinical trial expertise. Before joining the
Enigma team, Joel served as Director, QA/RA at Hologic, Inc. where in
addition to leading global quality and regulatory activities for the
Molecular Diagnostic Division, he also obtained FDA approval on products
including Cervista HPV and Inplex cystic fibrosis IVD tests. Joel received
his B.S. in Materials Engineering and Metallurgy from the University of
Florida in 1999.

"I am very pleased to welcome Joel to our Global Team," said John
McKinley, Chairman and CEO of Enigma. "His experience in achieving IVD
product regulatory approval will drive the quality systems and regulatory
approval necessary to deliver our molecular diagnostics point-of-care
systems. The new US Regional HQ at San Diego will support market penetration
across the USA and globally with our rapidly growing and diverse diagnostic
systems and future products."

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation
rapid molecular diagnostic instrument platforms for decentralized and
point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and
sensitivity of real-time PCR (polymerase chain reaction) with the simplicity
needed for decentralized and point-of-care testing providing results from a
raw sample in less than 60 minutes. The Company is targeting a number of
multi-billion pound markets, core among which are the Clinical and high-value
Applied Markets. Enigma's commercialisation strategy is to maximize revenues
from a continuous flow of market leading rapid diagnostic point-of- care
instrument and assay platforms, based on unique technologies and underpinned
by its broad Intellectual Property portfolio. Enigma will partner with market
leaders where global penetration of markets is required and where
appropriate, will engage regional partners and build in-house sales and
marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology
Laboratory to a portfolio of patents, which represent over 15 years of UK
Ministry of Defence funded Research. It also has licences from Applied
Biosystems and Celera Diagnostics for commercialisation of real-time PCR
instruments, and from Roche Molecular Systems to practise HybProbe real-time
PCR chemistry for human and veterinary in vitro diagnostics. Enigma's R&D
activities have generated a portfolio of worldwide patent families dedicated
to real-time PCR and wider molecular technologies. Many of these patents are
granted across a range of core commercial territories including US, EU and
Japan with more extensive filing and grants across a number of other key
territories.

For more information visit www.enigmadiagnostics.com.

    Contacts

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44-1980-590131

    US Contact:
    Tiberend Strategic Advisors, Inc.
    +1-212-827-0020
    Tamara Bright
    tbright@tiberendstrategicadvisors.com

UK: Deborah Cordingley of Enigma Diagnostics, +44-1980-590131, deborah.cordingley at enigmadiagnostics.com; or US: Tamara Bright of Tiberend Strategic Advisors, Inc., +1-212-827-0020, tbright at tiberendstrategicadvisors.com